Antiviral agent comprising RNA oligonucleotide
AssigneeKorea Advanced Institute of Science and Technology
InventorsByong-Seok Choi, Janghyun Lee
Life of this patent
Estimating the term…
Abstract
The present invention provides an antiviral agent comprising an RNA oligonucleotide having a particular sequence and structure. Specifically, when a cell line is treated with an RNA oligonucleotide having specific sequence and helical bend structure according to the present invention, the expression of interferon-β or ISG56 is increased and anti-viral activating is exhibited. Thus, a composition comprising the RNA oligonucleotide can be used as an antiviral agent.
Claims20
An antiviral agent comprising an RNA oligonucleotide as an active ingredient, wherein the RNA oligonucleotide comprises the base sequence represented by SEQ ID NO:1 (5′-N1GUAGAN2N3-3′) and the base sequence represented by SEQ ID NO:2 (5′-N4N5UUUGCN6-3′),
- wherein, the base sequences are bound to each other by a complementary binding to form double strands having a helical bend structure;
- the base sequences represented by SEQ ID NO:1 and SEQ ID NO:2 have a hydroxy (OH) group at the 5′-end thereof;
- and
- wherein N1 to N6 in the base sequence represented by SEQ ID NO:1 and SEQ ID NO:2 are selected from the group consisting of A, G, C, and U.
An antiviral agent comprising an RNA oligonucleotide as an active ingredient, wherein the RNA oligonucleotide comprises the base sequence represented by SEQ ID NO:1 (5′-N1GUAGAN2N3-3′) and the base sequence represented by SEQ ID NO:2 (5′-N4N5UUUGCN6-3′),
- wherein, the base sequences are bound to each other by a complementary binding to form double strands having a helical bend structure;
- the 3′-end of the base sequence represented by SEQ ID NO:1 and the 5′-end of the base sequence represented by SEQ ID NO:2 are connected into a loop to form a hairpin structure;
- the base sequence represented by SEQ ID NO:1 has a hydroxy (OH) group at the 5′-end thereof;
- and
- wherein N1 to N6 in the base sequence represented by SEQ ID NO:1 and SEQ ID NO:2 are selected from the group consisting of A, G, C, and U.
An antiviral agent comprising an RNA oligonucleotide as an active ingredient, wherein the RNA oligonucleotide comprises the base sequence represented by SEQ ID NO:17 (5′-N1GUAGAN2N3N4N5UUUGCN6-3′) formed by connecting the base sequence represented by SEQ ID NO:1 (5′-N1GUAGAN2N3-3′) and the base sequence represented by SEQ ID NO:2 (5′-N4N5UUUGCN6-3′),
- wherein, two base sequences represented by SEQ ID NO:17 are bound to each other by a complementary binding to form double strands having a helical bend structure;
- the base sequence represented by SEQ ID NO:17 has a hydroxy (OH) group at the 5′-end thereof;
- and
- wherein N1 to N6 in the base sequence represented by SEQ ID NO:17 are selected from the group consisting of A, G, C, and U.
Dependencies are inferred from the claim text.